KINIKSA PHARMACEUTICALS LTD
NASDAQ: KNSA (Kiniksa Pharmaceuticals Interna)
Last update: 2 hours ago96.33
0.05 (0.05%)
| Previous Close | 96.28 |
| Volume | 465,632 |
| Price / Earnings (Forward) | 60.64 |
| Price / Sales | 8.48 |
| Price / Book | 10.66 |
| 52 Weeks Range |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
AIStockmoo Score
| Value 30% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | 3.3 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Trading near its 52-week high. info | |
| Recent bearish reversal pattern: Hanging man. info | |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 1.6 |
| No clear net insider buying or selling. info | |
| Institutions net +7.26% of shares in their latest 13F filings: 198 holders increased, 110 decreased (quarter to 30 Sep 2026). info | |
| Short interest +13.4% from 31 Aug to 30 Oct 2026, 3.9 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is between support and resistance. Levels trending up. info | |
| Final Score | 1.54 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Kiniksa Pharmaceuticals Interna | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| KNSA | - | - | - | 10.66 |
| ALVO | - | - | - | - |
| BCRX | - | - | - | - |
| LQDA | - | - | - | 21.86 |
| RDHL | - | - | - | 0.570 |
| GELS | - | - | - | 0.430 |
Select this tab to load the latest available analysis.
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rubric Capital Management Lp | 30 Jun 2026 | 3,999,800 |
| Baker Bros. Advisors Lp | 30 Jun 2026 | 2,834,643 |
| Tang Capital Management Llc | 30 Jun 2026 | 2,259,889 |
| Spruce Street Capital Lp | 30 Sep 2026 | 918,070 |
| Pictet Asset Management Holding Sa | 30 Sep 2026 | 860,228 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEGNA MICHAEL R | - | 98.76 | -11,280 | -1,114,013 |
| MOAT ROSS | - | 90.80 | -27,977 | -2,540,312 |
| PAOLINI JOHN F. | - | 90.80 | -18,413 | -1,671,900 |
| PATEL SANJ K | - | 93.74 | -460,903 | -43,203,132 |
| RAGOSA MARK | - | 90.80 | -36,783 | -3,339,896 |
| Aggregate Net Quantity | -555,356 | |||
| Aggregate Net Value ($) | -51,869,253 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 93.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEGNA MICHAEL R | Officer | 09 Nov 2026 | Automatic sell (-) | 11,280 | 98.76 | 1,114,013 |
| MEGNA MICHAEL R | Officer | 09 Nov 2026 | Option execute | 11,280 | - | - |
| PATEL SANJ K | Officer | 04 Nov 2026 | Automatic sell (-) | 151,300 | 96.12 | 14,542,956 |
| PATEL SANJ K | Officer | 04 Nov 2026 | Option execute | 145,763 | - | - |
| PATEL SANJ K | Officer | 03 Nov 2026 | Automatic sell (-) | 220,170 | 93.29 | 20,539,659 |
| PATEL SANJ K | Officer | 03 Nov 2026 | Option execute | 130,326 | - | - |
| MOAT ROSS | Officer | 02 Nov 2026 | Automatic sell (-) | 27,977 | 90.80 | 2,540,312 |
| MOAT ROSS | Officer | 02 Nov 2026 | Option execute | 27,977 | - | - |
| PAOLINI JOHN F. | Officer | 02 Nov 2026 | Automatic sell (-) | 18,413 | 90.80 | 1,671,900 |
| PAOLINI JOHN F. | Officer | 02 Nov 2026 | Option execute | 18,413 | - | - |
| RAGOSA MARK | Officer | 02 Nov 2026 | Automatic sell (-) | 36,783 | 90.80 | 3,339,896 |
| RAGOSA MARK | Officer | 02 Nov 2026 | Option execute | 36,783 | - | - |
| PATEL SANJ K | Officer | 02 Nov 2026 | Automatic sell (-) | 89,433 | 90.80 | 8,120,516 |
| PATEL SANJ K | Officer | 02 Nov 2026 | Option execute | 53,381 | - | - |
| Show more | ||||||
Institutions
Institutional ownership: 109.38%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 198 | 7,140,706 |
| Decreased | 110 | 5,523,188 |
| New | 81 | 2,633,937 |
| Sold out | 26 | 693,278 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 4,294,644 | 3.9 |
| 15 Oct 2026 | 3,763,527 | 6.8 |
| 30 Sep 2026 | 3,778,657 | 6.4 |
| 15 Sep 2026 | 3,876,769 | 7.2 |
| 31 Aug 2026 | 3,788,699 | 8.7 |
| 14 Aug 2026 | 4,283,628 | 9.6 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m.… |
| 30 Oct 2026 | Yahoo Finance |
Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly Review
The stock market saw the major indexes ultimately fall for the week as Google, Amazon, Intel and ServiceNow led a tech wreck. But many sectors thrived. |
| 28 Oct 2026 | Yahoo Finance |
Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
Kiniksa Pharmaceuticals stock exploded 22.2% higher to US$89.20 on Wednesday after traders digested fresh Q3 2026 results. The move caps a strong recent run, yet the real story sits in the earnings print itself. ARCALYST revenue hit US$286 million for the quarter and net income reached US$47.3… |
| 27 Oct 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders. |
| 27 Oct 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary
Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q3 2026 earnings call… |
| 27 Oct 2026 | Yahoo Finance |
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance. |
| 27 Oct 2026 | Yahoo Finance |
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline. The company no… |
| 27 Oct 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 27 Oct 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth –– ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion –– KPL-387 pivotal Phase 3 data expected in 2H 2027 –– Conference call and webcast scheduled for 8:30 am… |
| 24 Oct 2026 | Yahoo Finance |
3 Healthcare Stocks To Watch In October 2026
Americans now have a record share of their financial assets in equities, which raises the stakes for choosing where every new dollar goes. With so much capital already tied to markets, investors are paying closer attention to sectors that can offer essential services through different economic… |
| 22 Oct 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio… |
| 17 Oct 2026 | Yahoo Finance |
GeneDx Holdings And 2 Other Top Healthcare Stocks
High interest costs are squeezing governments and households, yet healthcare remains a non‑discretionary spend that people rarely cut. That combination keeps attention on financially solid medical businesses with resilient demand for treatments, equipment and services. The opportunity is clear for… |
| 14 Oct 2026 | Yahoo Finance |
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. |
| 23 Sep 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a… |
| 17 Sep 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth. |
| 10 Sep 2026 | Yahoo Finance |
Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers. |
| 04 Sep 2026 | Yahoo Finance |
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time. A live webcast of… |
| 24 Aug 2026 | Yahoo Finance |
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. |
| 21 Aug 2026 | Yahoo Finance |
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |